VYNE Therapeutics Inc. (VYNE) has a consensus analyst rating of Buy, based on 2 analysts covering the stock. Of those, 1 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for VYNE is $5.75, representing a +827.6% upside from the current price of $0.6199. Price targets range from a low of $5.75 to a high of $5.75.
